The University of Missouri-Ellis Fischel Cancer Center (UM/EFCC) wishes to continue its participation in the clinical, translational, and basic research programs of the Cancer and Leukemia Group B (CALGB), as it has since 1969. The institutions in this grant include the UM/EFCC, our affiliated Harry S. Truman Veterans Administration Hospital, adjacent to the University Hospital, our sister medical school, the University of Missouri-Kansas City, and our CGOP affiliates, Missouri Hematology Associates of Columbia, Missouri Baptist Medical Center and St. Luke's Hospital of Saint Louis. (A new affiliate, the Kirksville College of Osteopathic Medicine, has been approved, but is not yet functional). Members of the UM/EFCC and our affiliates contribute to the group through participation on disease and modality committees, administrative committees, and through the protocol development process, serving as core committee members who originate the ideas behind studies, protocol chairs, and investigators who place patients on studies. Historically, UM/EFCC has been a major contributor to Respiratory Committee studies, and to a lesser extent, breast cancer studies. The recruitment of surgical oncologists to the center has resulted in an increase in gastrointestinal cancer studies. All leukemia and lymphoma patients are also considered for protocol participation. The research design involves the production of a protocol or treatment plan. The initial idea may arise from an individual or derive from a meeting of one of the CALGB disease committees (Breast, Gastrointestinal, Lung, Leukemia, Lymphoma, Prostate) or from a modality committee (Pharmacology and Experimental Therapeutics, Radiation Therapy, Surgery, and Psycho-oncology). The protocol is discussed, modified if necessary, and approved by the participating modality committees, and then by the Executive Committee. The final protocol is then submitted to the National Cancer Institute for approval. Following any additional changes the study is sent to the institutional Review Boards of the participating hospitals, and after approval implemented. Patients are then enrolled, treated, and followed until accrual goals are met at which time the protocol is closed. The results are then tabulated, statistically analyzed, and subsequently published. Sequential studies build upon the results of prior completed trials. The group also participates in CALGB Prevention Studies and all possible studies are activated to meet patient needs and enhance accrual.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA012046-28
Application #
6172581
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1979-04-01
Project End
2003-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
28
Fiscal Year
2000
Total Cost
$132,087
Indirect Cost
Name
University of Missouri-Columbia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
112205955
City
Columbia
State
MO
Country
United States
Zip Code
65211
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Jaklitsch, Michael T; Gu, Lin; Demmy, Todd et al. (2013) Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. J Thorac Cardiovasc Surg 146:9-16
Nixon, Andrew B; Pang, Herbert; Starr, Mark D et al. (2013) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res 19:6957-66
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Gupta, Pankaj; Mulkey, Flora; Hasserjian, Robert P et al. (2013) A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). Invest New Drugs 31:1311-20
Boylan, Alice M; Wang, Xiaofei F; Ko, Richard et al. (2013) Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. J Thorac Cardiovasc Surg 146:206-11
Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54

Showing the most recent 10 out of 100 publications